Willow Biosciences Inc (TSE:ATLE)
:ATLE
Top Page
Willow Biosciences Inc
(ATLE)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$0.15
▼(-16.67% Downside)
Action:ReiteratedDate:12/07/25
The overall stock score is primarily impacted by significant financial challenges, including negative equity and ongoing losses, which are major concerns. However, positive technical indicators and favorable corporate events provide some optimism for future performance.
Positive Factors
Rapid Revenue Growth
A nearly 300% revenue increase signifies accelerating product adoption and expanding customer traction for Willow's fermentation-derived ingredients. This durable top-line momentum supports scale effects, improves leverage on fixed costs, and strengthens the case for continued commercial expansion over the next several months.
Negative Factors
Negative Shareholders' Equity
Negative equity indicates solvency strain and weak balance sheet resilience. This structural weakness limits borrowing capacity, raises creditor and investor concerns, and increases the likelihood of dilutive financing or onerous terms—factors that materially affect strategic flexibility for months ahead.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
A nearly 300% revenue increase signifies accelerating product adoption and expanding customer traction for Willow's fermentation-derived ingredients. This durable top-line momentum supports scale effects, improves leverage on fixed costs, and strengthens the case for continued commercial expansion over the next several months.
Read all positive factors
Willow Biosciences Inc (ATLE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$56.36M
Dividend YieldN/A
Average Volume (3M)26.24K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth26.91%
EPS Growth81.01%
CountryCA
Employees19
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding352,222,660
10 Day Avg. Volume47,704
30 Day Avg. Volume26,236
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Willow Biosciences Inc Business Overview & Revenue Model
Company Description
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, a...
How the Company Makes Money
Willow Biosciences Inc. generates revenue through several key streams. Primarily, the company monetizes its proprietary biosynthesis technology by entering into partnerships and licensing agreements with other companies in the pharmaceutical and n...
Willow Biosciences Inc Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
25
Negative
Cash Flow
30
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Willow Biosciences Inc Technical Analysis
Negative
0.18
Price Trends
0.16
Positive
0.16
Negative
0.17
Negative
Market Momentum
<0.01
Negative
50.23
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ATLE, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.16, and above the 200-day MA of 0.17, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.23 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ATLE.
Willow Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | C$75.00M | -14.53 | 12.78% | ― | 15.11% | ― | |
59 Neutral | C$68.11M | -6.17 | -21.73% | ― | 43.56% | -349.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | C$56.36M | -2.79 | -19.76% | ― | 26.91% | 81.01% | |
42 Neutral | C$34.86M | -0.41 | -2.21% | ― | -6.05% | ― | |
42 Neutral | C$63.34M | -16.32 | ― | ― | -62.34% | 9.80% |
* General Sector Average
TSE:ATLE
Willow Biosciences Inc
0.16
0.11
226.53%
TSE:IAN
iAnthus Capital Holdings
0.01
0.00
0.00%
TSE:QNTM
Quantum Biopharma
4.85
-4.17
-46.23%
TSE:DB
Decibel Cannabis Company
0.13
0.08
136.36%
TSE:VEXT
Vext Science
0.28
0.13
89.66%
TSE:BNXT
BioNxt Solutions
0.52
0.11
26.83%
Willow Biosciences Inc Corporate Events
Business Operations and StrategyFinancial Disclosures
Atlas Energy Corp. Expands Deal Pipeline Amid Favorable Market Conditions
Positive
Nov 14, 2025
Atlas Energy Corp. has released its unaudited consolidated interim financial statements for the third quarter of 2025, highlighting a favorable market environment for disciplined capital deployment due to moderated global oil prices and potential ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.